Gadofosveset Trisodium for Heart Imaging Studies

Status Completed

Clinical Trial Summary

Background:

- Magnetic resonance imaging (MRI) is type of imaging study that uses magnetic fields and radio waves to take pictures of the body. To help the images show up more clearly, a contrast agent is injected into a vein. Researchers are interested in finding contrast agents that can help show problems with the blood vessels around the heart. They want to test an agent called Gadofosveset Trisodium to see how it works in MRI scans.

Objectives:

- To test the effectiveness of Gadofosveset Trisodium as a contrast agent in heart MRI scans.

Eligibility:

- Healthy volunteers between 18 and 45 years of age.

Design:

- Participants will be screened with a physical exam and medical history. They will provide blood samples before the scanning sessions.

- Participants will have an MRI scan after the screening visit. They will have a dose of the contrast scan before the study.

- Participants will return for one additional MRI scan within 1 to 2 months of each scan. Different doses of the contrast agent will be used for each scan.

- An additional blood sample will be collected within 1 week of the second MRI scan.

Clinical Trial Description

The purpose of this study is to determine if the diagnostic quality of contrast-enhanced coronary magnetic resonance angiography (MRA) is improved by using a higher versus a lower dose of a gadolinium-based contrast agent. We will compare two doses of an intravascular contrast agent (Gadofosveset, 0.03 and 0.06 mmol/kg) in this pilot dosing study. Healthy participants will be recruited who do not have a clinical indication for MR angiography but do have safety clearance for IV gadolinium contrast and MR scanning.

Subjects will be evaluated in order to determine if the signal to noise ratio (SNR) and contrast to noise ratio (CNR) of the coronary arteries is increased for the higher dose contrast agent. Parameters will be compared with paired t-testing for significance. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01853592
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase
Start date	March 8, 2013
Completion date	December 13, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00069654` - Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease	Phase 2
Completed	`NCT02919124` - Epicardial Echocardiography of Coronary Anastomoses Using the Echoclip Device	N/A
Recruiting	`NCT02639962` - Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study	N/A
Completed	`NCT02494557` - Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients	N/A
Recruiting	`NCT01466452` - Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery	Phase 2
Completed	`NCT01182428` - XIENCE V: SPIRIT WOMEN Sub-study	Phase 4
Completed	`NCT00368953` - YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus	Phase 4
Completed	`NCT00371891` - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)	Phase 4
Completed	`NCT00319449` - Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)	Phase 4
Completed	`NCT00091754` - Atherosclerosis, Plaque and CVD in Communities
Completed	`NCT00069797` - Epidemiology of Coronary Heart Disease in Men Aged 40 and Over	N/A
Completed	`NCT00037245` - Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA	N/A
Completed	`NCT00024596` - Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)	N/A
Completed	`NCT00006502` - Myocardial Perfusion, Risk Factors, and Coronary Calcium	N/A
Withdrawn	`NCT00006497` - Long-Term Effects of Subclinical CAD on Cardiac Function
Completed	`NCT00006407` - Sex Steroid Hormones and Risk of CHD in Women	N/A
Completed	`NCT00006309` - Pooling of Cohort Studies on Diet & Coronary Disease	N/A
Completed	`NCT00005269` - Family Blood Pressure Program - GENOA
Completed	`NCT00000508` - Stanford Coronary Risk Intervention Project (SCRIP)	Phase 3
Completed	`NCT00005147` - Epidemiology of Atherosclerosis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.